Clinical Trial Update: Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating personalized duration of consolidation durvalumab guided by circulating tumor DNA in stage III non-small cell lung cancer has been wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: Indiana University | Conditions: NSCLC, Stage III | Phase 2 | Status: WITHDRAWN